These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 21947806

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I.
    BMJ; 2013 Jul 23; 347():f4678. PubMed ID: 23881948
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Why have UK doctors been deterred from prescribing Avastin?
    Cohen D.
    BMJ; 2015 Apr 01; 350():h1654. PubMed ID: 25834024
    [No Abstract] [Full Text] [Related]

  • 6. A licence to cure.
    Aronson JK, Ferner RE.
    BMJ; 2015 Apr 01; 350():h1723. PubMed ID: 25834026
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Ophthalmology; 2014 Apr 01; 121(4):936-45. PubMed ID: 24405740
    [Abstract] [Full Text] [Related]

  • 8. Legal. PCTs taken to court over use of cheaper drug.
    Calkin S.
    Health Serv J; 2012 Apr 26; 122(6303):10-1. PubMed ID: 22741353
    [No Abstract] [Full Text] [Related]

  • 9. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
    Torjesen I.
    BMJ; 2012 Apr 24; 344():e2959. PubMed ID: 22532011
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
    IVAN Study InvestigatorsInstitute of Clinical Science, The Queen's University of Belfast, Belfast, Ireland. u.chakravarthy@qub.ac.uk, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC.
    Ophthalmology; 2012 Jul 24; 119(7):1399-411. PubMed ID: 22578446
    [Abstract] [Full Text] [Related]

  • 13. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
    Moreno TA, Kim SJ.
    Semin Ophthalmol; 2016 Jul 24; 31(4):378-84. PubMed ID: 27116030
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Avastin and Lucentis: a guide through the legal maze.
    Lock D.
    BMJ; 2015 Apr 01; 350():h1377. PubMed ID: 25834023
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
    Hawkes N.
    BMJ; 2012 Jul 30; 345():e5161. PubMed ID: 22846417
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.